MADISON: How Wisconsin Can Maintain Its Lead in Stem Cell Research
Tom Still, 02/16/04

MADISON – South Korea is a nation deeply imbued with Confucian values, such as the belief that human bodies are
inherited from ancestors and should never be tampered with. So there was understandable culture clash in Seoul last
week when South Korean researchers announced they had become the first to clone a mature, human embryo – and then
collect from it master stem cells in a process that may someday let patients grow their own replacement tissues.

For every South Korean who raised questions about the breakthrough, there appeared to be another who was overcome with
pride. South Korea is a nation that rose from the ashes of war 50 years ago to become a global manufacturing and
technology leader – and its people relish being first.

“This proves that South Koreans are ahead of everyone else in the world in this field,” boasted Moon Shin-yong, who led
the research team at Seoul National University. Hwang Yoon-young, the dean of Seoul’s Hanyang University Medical
School, proclaimed that the young women who donated their eggs for research will have their “sacred names … inscribed
in the monument for South Korean biotechnology.”

No one got quite that worked up in 1998 when Jamie Thomson, the soft-spoken professor at the UW-Madison, announced his
laboratory team had become the first to isolate stem cells from human embryos and coax them to grow in five “immortal”
cell lines. But it was that accomplishment, and the work of other scientists who followed, that laid the foundation for
the South Korean discovery.

But is it true that stem cell researchers in Wisconsin and elsewhere must now take a back seat to those in South Korea?
Has Wisconsin squandered its head start in stem cell research?

The answer is a qualified “no.” While Wisconsin faces stiff competition from around the world and from within the
United States, its researchers have a comprehensive program that has operated successfully under tight scrutiny and
ethical oversight. If other overreaching programs are tarred as rogues for moving too quickly or too brashly, the
Wisconsin stem cell program will remain No. 1 on the quality list.

Stem cell research has raised hopes for treating Alzheimer’s and Parkinson’s disease, diabetes, heart disease and more.
At least 30 faculty at the UW-Madison conduct stem cell research stem cells and another 120 researchers and staff
assist in the effort. Collectively, their projects earn about $15 million to $20 million a year in grants from federal
sources, research foundations and private donors.

The Wisconsin Alumni Research Foundation, the private, non-profit patent and license arm of the UW-Madison, has created
the WiCell Research Institute. This WARF subsidiary has another dozen stem cell researchers. The institute has
distributed stem cells to 150 other research institutions and also conducts regular training sessions on how to work
with them.

Because WARF holds key stem cell patents and controls technology transfer for UW-Madison, it can protect Wisconsin’s
intellectual property – and issue commercial licenses to use the technology. Such spin-offs haven’t happened yet, but
that someday will become another important “first” for Wisconsin.

That would be an important breakthrough for people everywhere. Once stem cell therapies are licensed, treatments cannot
be far behind.

The South Korea challenge may not be the most significant to Wisconsin, however. In California, voters are being asked
to approve a bond referendum that would spend $3 billion over 10 years on stem cell research. The University of
Minnesota’s Stem Cell Institute recently announced a drive to expand its work. Ohio, New Jersey and Pennsylvania are
among other states pursuing programs to ramp up their stem cell research.

Short of an academic “raid” that would pilfer top Madison researchers, or a short-sighted legislative initiative that
would tie the hands of those researchers, Wisconsin remains in an esteemed position in the stem cell research
community. And if researchers here are the first to discover a treatment or cure, that “first” will be the only one
that truly counts.

Still is president of the Wisconsin Technology Council. He is the former associate editor of the Wisconsin State
Journal in Madison.

SOURCE: Wisconsin Technology Network, United States
http://www.wistechnology.com/column.php?id=583

* * *

----------------------------------------------------------------------
To sign-off Parkinsn send a message to: mailto:[log in to unmask]
In the body of the message put: signoff parkinsn